8-K: Moleculin Accelerates 2026 Outlook with Pivotal Trial Unblinding

Moleculin Biotech announces accelerated 2026 outlook, including first pivotal trial unblinding, global expansion, and new externally funded clinical programs for Annamycin and WP1066.

Summary

• Moleculin Biotech, Inc. (Nasdaq: MBRX) provided a business outlook and upcoming milestones for its drug candidates Annamycin and WP1066.
• Annamycin, a next-generation non-cardiotoxic anthracycline, is in a pivotal Phase 3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (R/R AML).
• The MIRACLE trial has expanded globally to nine countries (US, Spain, Italy, Poland, Czechia, Romania, Ukraine, Lithuania, Georgia) with over 46 sites selected.
• First unblinding of data for 45 subjects in Part A of the MIRACLE trial is expected in Q1 2026.
• A second unblinding for 90 subjects in Part A of the MIRACLE trial is expected in Q3 2026.
• An investigator-initiated trial (IIT) for Annamycin in third-line pancreatic cancer, funded by Atlantic Health, is expected to start in 2H 2026.
• WP1066, an Immune/Transcription Modulator, is in a Phase 2 trial for GBM (brain cancer) at Northwestern University, which is externally funded.
• A follow-on Phase 2 pediatric brain tumor trial for WP1066 is expected to begin at Emory University in 2H 2026, also externally funded.
• Preclinical data on a WP1066 intravenous (IV) formulation is expected in 2H 2026.
• The accelerated timeline for the MIRACLE trial's first unblinding is due to positive investigator recruitment response in December meetings.

Sentiment

Score: 7

Explanation: The filing presents a generally positive outlook with accelerated trial timelines and external funding for multiple programs, indicating good operational progress. However, the explicit mention of requiring significant additional financing without commitments introduces a notable financial risk, tempering the overall sentiment.

Positives

• First pivotal trial unblinding for Annamycin (MIRACLE trial) is on track for Q1 2026.
• Global trial expansion for Annamycin to nine countries and over 46 sites.
• Multiple clinical programs for Annamycin and WP1066 are externally or investigator-initiated trial (IIT) funded, reducing company costs.
• Annamycin has potential to be the world's first non-cardiotoxic anthracycline, addressing a significant market opportunity given current cardiotoxic treatments.
• Initial efficacy of Annamycin demonstrated in previous trials for 2L AML and soft tissue sarcoma metastases.
• Positive results from a Phase 1 WP1066 trial at Emory University were recently published, leading to interest in a follow-on trial.
• The MIRACLE trial timeline for the first unblinding has been accelerated due to positive investigator recruitment response.
• The company believes it has substantially de-risked the development pathway for Annamycin for AML with FDA input.

Negatives

• The company will require significant additional financing, for which it has no commitments, to conduct its clinical trials as described.
• Milestones described assume the company's ability to secure such financing on a timely basis.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, including those discussed in their Form 10-K.

Risks

• Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described.
• The milestones described in this press release assume the Company's ability to secure such financing on a timely basis.
• Expectations reflected in forward-looking statements may prove to be materially different from actual results.
• Known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. Risk Factors in their most recently filed Form 10-K and updated in Form 10-Q filings and other public filings with the SEC.
• The MIRACLE study, as all clinical trials, is subject to appropriate future filings with and potential additional feedback from the FDA and their foreign equivalents.

Future Outlook

Moleculin Biotech anticipates significant progress in 2026, including the first unblinding of pivotal trial data for Annamycin in Q1, global expansion of the MIRACLE trial, and the initiation of new externally funded clinical programs for both Annamycin (pancreatic cancer) and WP1066 (pediatric brain tumors). The company expects to reach primary efficacy data for MIRACLE and begin a rolling NDA in 2028.

Management Comments

• "The two MIRACLE data readouts will set the course for the pivotal trial in two ways – potentially demonstrating the efficacy of the Annamycin arms versus the control arm and setting the dose for the Annamycin arm to be used in Part B of the MIRACLE trial." Walter Klemp, Chairman and CEO.
• "We have already demonstrated initial efficacy in 2L AML and in soft tissue sarcoma metastases in previous trials so planning an expansion into pancreatic cancer will continue adding to the Annamycin story as a next generation anthracycline." Walter Klemp, Chairman and CEO.
• "We view this kind of institutional funding of clinical research to be a strong independent endorsement of the potential for Annamycin." Walter Klemp, Chairman and CEO.
• "Importantly, we believe Annamycin has the potential to become the world’s first ever non-cardiotoxic anthracycline and we are expecting more data supporting its lack of cardiotoxicity to be presented early this year." Walter Klemp, Chairman and CEO.
• "Considering that nearly half of all cancers and 60% of all childhood cancers are currently treated with cardiotoxic anthracyclines that are known to result in permanent heart damage, we think that makes the market opportunity for Annamycin potentially enormous." Walter Klemp, Chairman and CEO.
• "We are extremely grateful to these two great institutions for their willingness to fund further investigator-initiated clinical activity with WP1066, which has been the focus of over 55 peer reviewed research papers." Walter Klemp, Chairman and CEO.
• "Despite its importance, STAT3 has been called an undruggable target. We believe WP1066 has the potential to solve this issue." Walter Klemp, Chairman and CEO.
• "Looking forward to 2026, we anticipate the current trial at Northwestern to continue treating subjects and for a second Emory trial to begin in 2026." Walter Klemp, Chairman and CEO.

Industry Context

The development of non-cardiotoxic anthracyclines like Annamycin addresses a critical unmet need in oncology, as current anthracycline treatments, used in a significant portion of cancer cases, are known to cause permanent heart damage. This positions Annamycin to potentially capture a large market share if successful. The focus on "undruggable" targets like STAT3 with WP1066 also aligns with advanced oncology research seeking novel mechanisms to combat aggressive cancers like GBM and pancreatic cancer, which often have poor prognoses. The reliance on investigator-initiated trials (IITs) and external funding reflects a common strategy for smaller biotech companies to advance their pipeline while conserving capital, leveraging academic and institutional interest in promising drug candidates.

Comparison to Industry Standards

• Annamycin aims to be the world's first non-cardiotoxic anthracycline, a significant differentiator from existing cardiotoxic anthracyclines commonly used in nearly half of all cancers and 60% of childhood cancers.
• WP1066 targets STAT3, c-Myc, and HIF-1, which are widely sought but often considered "undruggable" targets in cancer research, potentially offering a novel approach compared to current therapies for brain tumors and pancreatic cancer.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful, but also dilution risk due to future financing needs. Positive news on trial progress and external funding could boost investor confidence.
• Patients (AML, Pancreatic, Brain Cancer): Potential for new, less toxic, and more effective treatment options, especially for hard-to-treat cancers and those currently treated with cardiotoxic drugs.
• Employees: Continued employment and potential growth opportunities as drug development progresses.
• Healthcare Providers/Researchers: Access to new investigational drugs and opportunities to participate in cutting-edge clinical research, particularly through IITs.
• Regulatory Authorities (FDA, etc.): Ongoing engagement and review of clinical trial data and future regulatory submissions.

Next Steps

• Q1 2026: Independent expert review of Annamycin non-cardiotoxicity data.
• Q1 2026: Unblinding of data for the first 45 subjects in Part A of the MIRACLE trial.
• 1H 2026: Recruitment of the 90th subject in the MIRACLE trial.
• Q3 2026: Unblinding of data for 90 subjects in Part A of the MIRACLE trial.
• 2H 2026: Start of Part B of the MIRACLE trial.
• 2H 2026: Initiation of Atlantic Health's pancreatic cancer clinical trial for Annamycin.
• 2H 2026: Initiation of Emory's Phase 2 pediatric brain tumor trial for WP1066.
• 2H 2026: Release of preclinical data on WP1066 IV formulation.
• 2027: Begin recruitment of 3rd line AML subjects for Annamycin.
• 2027: End recruitment of Part B of MIRACLE trial.
• 2027: Begin pediatric AML clinical study for Annamycin.
• 2028: Primary efficacy data for MIRACLE trial.
• 2028: Begin rolling NDA for Annamycin.

Key Dates

Recommendation

The filing contains significant positive news regarding accelerated clinical trial timelines, global expansion, and external funding for key drug candidates, which could drive future value. Annamycin's potential as a non-cardiotoxic anthracycline addresses a large market need. However, the explicit disclosure of requiring "significant additional financing" with "no commitments" introduces a substantial financial risk and potential for dilution. While the clinical progress is encouraging, the financing uncertainty warrants a "hold" recommendation, advising investors to monitor the company's ability to secure necessary funding before making further investment decisions.

Keywords

Moleculin Biotech, MBRX, Annamycin, naxtarubicin, WP1066, AML, Acute Myeloid Leukemia, Pancreatic Cancer, Brain Cancer, GBM, Glioblastoma, Anthracycline, Non-cardiotoxic, STAT3 inhibitor, Clinical Trial, Phase 3, MIRACLE trial, Oncology, Pharmaceutical, Biotech, Drug Development, FDA, SEC Filing